Low-dose interferon-α accelerates atherosclerosis in an LDL receptor-deficient mouse model

European Journal of Internal Medicine

Volumn 14, Issue 8, 2003, Pages 479-483

  Levy, Zohar ^a   Rachmani, Rita ^a   Trestman, Svetlana ^a   Dvir, Ayana ^a   Shaish, Aviv ^b   Ravid, Mordchai ^a   Harats, Dror ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Interferon ; Murine model

Indexed keywords

ALPHA INTERFERON; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; MOUSE; NONHUMAN; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 1142309731     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2003.08.010     Document Type: Article

References (29)

1. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:2001;1876-1890.
2. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
3. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T-lymphocytes from human atherosclerotic plaques recognize oxidized LDL. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3893-3897.
4. Jonasson L., Holm J., Skalli O., Bondjers G., Hansson G.K. Regional accumulations of T cells, macrophages and smooth muscle cells in human atherosclerotic plaque. Arteriosclerosis. 6:1986;131-138.
5. Frostegard J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U.et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophages stimulating cytokines. Arteriosclerosis. 145:1999;33-45.
6. Mosmann T.R., Cherweanki H., Bond M.W. Two types of murine helper T cell clone I: definition, according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:1986;2348-2357.
7. Ashkar S., Weber G.F., Panousakopoulou V., Sanchirico M.E., Janasson M., Zawaideh S.et al. Eta-1(osteopontin): an early component of type-1 (cell mediated) immunity. Science. 287:2000;860-864.
8. Koichi U., Demer L.L., Castle S.C., Jullien D., Berliner J.A., Gately M.K.et al. Cross-regulatory roles of interleukin(IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97:1996;2130-2138.
9. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariety J. et al. In vivo downregulation of T helper cell 1 immune responses reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation. 104:2001;197-202.
10. Pfeffer L.M., Dinarello C.A., Heberman R.B., Willams B.R.G., Borden E.C., Borden R.et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58:1998;2489-2499.
11. Whitman S.C., Ravisankar P., Elam H., Daugherty A. Exogenous interferon-γ enhances atherosclerosis in apo E-/- mice. Am. J. Pathol. 157:2000;1819-1824.
12. Tellides G., Tereb D.A., Kirkilies-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S.et al. Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature. 403:2000;207-211.
13. Gupta S., Pablo A.M., Jiang X.-C., Wang N., Tall A.R., Schindler C. IFN-γ potentiates atherosclerosis in apo E knock-out mice. J. Clin. Invest. 99:1997;2752-2761.
14. Cousens L.P., Orange J.S., Su H.C., Biron G.A. Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. U. S. A. 94:1997;634-639.
15. McRae B.L., Semnani R.T., Hayes M.P., van Seventer G.A. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 development. J. Immunol. 160:1998;4298-4304.
16. Ishibashi S., Goldstein J.L., Brown M.S., Herz J., Burns D.K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1994;1885-1893.
17. Renhberg E., Kelder B., Hoal E.G., Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J. Biol. Chem. 257:1982;11457-11502.
18. Dinney C.P.N., Bielenberg D.R., Perrotte P., Reich R., Eve B.Y., Bucana C.D.et al. Inhibition of basic fibroblast growth factor expression, angiogenesis and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58:1998;808-814.
19. Robert W.F.J., Srecko K. Systemic effects of orally administered interferons and interleukin-2. J. Interferon and Cytokine Res. 9:1999;829-839.
20. Feingold K.R., Mounzer S., Serio M.K., Moser A.H., Dinarello C.A., Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology. 125:1989;267-274.
21. Grunfeld C., Dinarello C.A., Feingold K.R. Tumor necrosis factor-α, interleukin-1 and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism. 40:1991;894-898.
22. Grunfeld C., Soued M., Adi S., Moser A.H., Fiers W., Dinarello C.A. Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-α Cancer Res. 51:1991;2803-2807.
23. Feingold K.R., Dorrler W., Dinarello C.A., Fiers W., Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin 1 and the interferons is blocked by inhibition of prostaglandin synthesis. Endocinology. 130:1992;10-16.
24. Consuelo F.M., Gregorio C., Carlos G., Inmaculada F., Natalia S., Sagrarion L.et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α Am. J. Gastroenterol. 93:1998;1901-1904.
25. Sgarabotto D., Vianello F., Stefani P.M., Scano F., Sartori R., Caenazzo A.et al. Hypertriglyceremia during long term interferon-α therapy in a series of hematologic patients. J. Internat. Cytol. Res. 17:1997;241-244.
26. Junghans V., Runger T.M. Hypertriglyceremia following adjuvant interferon treatment in two patients with malignant melanoma. Br. J. Dermatol. 140:1999;168-192.
27. Shinohara E.S., Kihara S., Hirano K.I., Ishigami M., Arai T., Nozaki S. et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesterol ester transfer protein activities in patients with chronic hepatitis C. Hepatology. 25:1997;1502-1506.
28. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., Biron C.A. Interferon α/β-mediated inhibition and promotion of interferon γ: STAT1 resolves a paradox. Nature Immunol. 1:2001;7076.
29. Godoc V., Harraga S., Podoprigora G., Liance M., Bardonnet K., Vuitton D.A. INFα-29 protects mice against a helmint infection of the liver and nodulates immune responses. Gastroenterology. 124:2003;1441-1450.